Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months

Human Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 364-369

  Neuner, Irene ^a,b,d   Nordt, Carlos ^c   Schneider, Frank ^a,d   Kawohl, Wolfram ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d JARA Brain Translational Brain Medicine   (Germany)

Author keywords

antipsychotics; aripiprazole; tachyphylaxia; tic; Tourette

Indexed keywords

ARIPIPRAZOLE; PROPRANOLOL;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOURETTE SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864119652     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2235     Document Type: Article

References (32)

1. Brown H,. 1999. Applied mixed models in medicine. Wiley and Sons: Chichester.
2. Bruun RD,. 1988. The natural history of Tourette's syndrome. In Tourette's syndrome and Tic disorders. Clinical understanding and treatment, Cohen DJ, Bruun RD, Leckman JF, (eds). Wiley: New York; 21-39.
3. Budman C, Coffey BJ, Shechter R, et al., 2008. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 18: 509-515.
4. Burris KD, Molski TF, Xu C, et al., 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.
5. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ,. 2010. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 25: 179-186.
6. Davies L, Stern JS, Agrawal N, Robertson MM,. 2006. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 21: 447-453.
7. Farde L, Wiesel FA, Halldin C, Sedvall G,. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76.
8. Frolich J, Starck M, Banaschewski T, Lehmkuhl G,. 2010. Aripiprazole-a medical treatment alternative for Tourette Syndrome in childhood and adolescence. Z Kinder Jugendpsychiatr Psychother 38: 291-298.
9. Janouschek H, Vernaleken I, Boy C, et al., 2006. Das temporale und extrastriatale D2/D3-Rezeptor-Bindungsprofil von Aripiprazol bei Patienten mit schizophrener oder schizoaffektiver Psychose. Der Nervenarzt 77: S160.
10. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA,. 2002. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137-140.
11. Kawohl W,. 2010. Gilles de la Tourette-syndrome: treatment of a neuropsychiatric disorder. Praxis (Bern 1994) 99: 1353-1360.
12. Kawohl W, Podoll K,. 2008. Contour copying or echoplasia - a new echo phenomenon in a person with Gilles de la Tourette syndrome. Psychopathology 41: 201-202.
13. Kawohl W, Bruhl A, Krowatschek G, Ketteler D, Herwig U,. 2009a. Functional magnetic resonance imaging of tics and tic suppression in Gilles de la Tourette syndrome. World J Biol Psychiatry 10: 567-570.
14. Kawohl W, Schneider F, Vernaleken I, Neuner I,. 2009b. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry 10: 827-831.
15. Kawohl W, Schneider F, Vernaleken I, Neuner I,. 2009c. Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 21: 224.
16. Kenny DA, Bolger N, Kashy DA,. 2002. Traditional methods for estimating multilevel models. In Modeling intraindividual variability with repeated measures data: methods and applications, Hershberger SL, Moskowitz DS, (eds). Lawrence Erlbaum Associates: New Jersey.
17. Kim SH, Han DH, Joo SY, Min KJ,. 2010. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol 25: 187-190.
18. Leckman JF, Riddle MA, Hardin MT, et al., 1989. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28: 566-573.
19. Lyon GJ, Samar S, Jummani R, et al., 2009. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19: 623-633.
20. Madhusoodanan S, Parida S, Jimenez C,. 2010. Hyperprolactinemia associated with psychotropics - a review. Hum Psychopharmacol 25: 281-297.
21. Mesulam MM, Petersen RC,. 1987. Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. Neurology 37: 1828-1833.
22. Miranda CM, Castiglioni TC,. 2007. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients. Rev Med Chil 135: 773-776.
23. Müller N,. 2004. Tics. In Bewegungsstörungen bei psychischen Erkrankungen, Jahn T, (ed). Springer: Berlin, Heidelberg, New York; 215-231.
24. Neuner I, Ludolph A,. 2009. Tics and Tourette's syndrome throughout the life span. Nervenarzt 80: 1377-1387. quiz 1388.
25. Neuner I, Kellermann T, Stocker T, et al., 2010a. Amygdala hypersensitivity in response to emotional faces in Tourette's patients. World J Biol Psychiatry 11: 858-872.
26. Neuner I, Kupriyanova Y, Stocker T, et al., 2010b. White-matter abnormalities in Tourette syndrome extend beyond motor pathways. Neuroimage 51: 1184-1193.
27. Pae CU,. 2009. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 8: 373-386.
28. Rickards H, Robertson M,. 2003. A controlled study of psychopathology and associated symptoms in Tourette syndrome. World J Biol Psychiatry 4: 64-68.
29. Rothenberger A, Banaschewski T,. 2003. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter., Dgkjp, (eds). Deutscher Ärzte Verlag.
30. Seo WS, Sung HM, Sea HS, Bai DS,. 2008. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 18: 197-205.
31. Shapiro AK, Shapiro E,. 1968. Treatment of Gilles de la Tourette's Syndrome with haloperidol. Br J Psychiatry 114: 345-350.
32. Werner CJ, Stocker T, Kellermann T, et al., 2010. Altered amygdala functional connectivity in adult Tourette's syndrome. Eur Arch Psychiatry Clin Neurosci 260 (Suppl 2): S95-99.